Pacira | PCRX - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Assertio Holdings USD 105.8M 12.5M 2025-09
Astellas Pharma JPY 1.76T 150.69B 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Cara Therapeutics USD 32.93M 41M 2025-06
Coherus Biosciences USD 61.01M 26.76M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Ironwood Pharmaceuticals USD -264.16M 44M 2025-09
J&J USD 78.47B 0 2025-09
Ligand Pharmaceuticals USD 1.02B 67.04M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novo Nordisk DKK 194.05B 24.15B 2025-12
Omeros USD -228.68M 15.13M 2025-06
Pacira USD 693.11M 34.1M 2025-12
Perrigo USD 2.94B 1.51B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Supernus Pharmaceuticals USD 1.06B 12.05M 2025-12
Teva Pharmaceutical Industries USD 7.91B 664M 2025-12
Xeris Pharmaceuticals USD 13.69M 14.55M 2025-12
Xoma USD 87.94M 15.5M 2025-09
Zoetis USD 3.33B 2.07B 2025-12